Validation and refinement of the Baveno VII criteria for risk stratification in compensated advanced chronic liver disease after HCV-cure

Background Baveno-VII has established criteria for excluding clinically significant portal hypertension (CSPH) after HCV-cure in compensated advanced chronic liver disease (cACLD, post-treatment liver stiffness measurement (LSM) <12kPa & platelet count (PLT) >150G/L). In contrast, post-treatment LSM values ≥25kPa indicate CSPH and a substantial risk of hepatic decompensation, despite HCV-cure. However, the long-term prognostic value of these criteria has yet to be independently validated and determinants of decompensation in the gray zone have yet to be identified.